6-(morpholinomethyl)benzo[d]thiazol-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 6-(morpholinomethyl)benzo[d]thiazol-2-amine
• 英文别名: 6-(4-Morpholinylmethyl)-1,3-benzothiazol-2-ylamine；6-(morpholin-4-ylmethyl)-1,3-benzothiazol-2-amine
• 化学式: C₁₂H₁₅N₃OS
• mdl: MFCD09702742
• 分子量: 249.337
• InChiKey: NBRSJRZIOVIFIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  79.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(morpholinomethyl)benzo[d]thiazol-2-amine 在 吡啶 、 一水合肼 、 溶剂黄146 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 为溶剂， 反应 12.5h， 生成 (E)-N-(6-(morpholinomethyl)benzo[d]thiazol-2-yl)-2-(2-hydroxybenzylidene)hydrazinecarboxamide
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents

  摘要：

  A series of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety were designed and synthesized and their cytotoxic activities against five cancer cell lines (NCI-H226, SK-N-SH, HT29, MKN45, and MDA-MB-231) were screened in vitro. Most of them showed moderate to excellent activity against all the tested cell lines. Among them, compounds 15g (procaspase-3 EC50 = 1.42 mu M) and 16b (procaspase-3 EC50 = 0.25 mu M) exhibited excellent antitumor activity with IC50 values ranging from 0.14 mu M to 0.98 mu M against all cancer cell lines, which were 1.8-8.7 times more active than the first procaspase activating compound (PAC-1) (procaspase-3 EC50 = 4.08 mu M). The structure activity relationship (SAR) analyses indicated that the introduction of a lipophilic group (a benzyloxy or heteroaryloxy group) at the 4-position of the 2-hydroxy phenyl ring was beneficial to antitumor activity, and the presence of substituents containing nitrogen that are positively charged at physiological pH could also improve antitumor activity. It was also confirmed that the steric effect of the 4-position substituent of the benzyloxy group had a significant influence on cytotoxic activity. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.08.058
• 作为产物：
  描述：

  4-(4-硝基苄基)吗啡啉 在 溴 、 氯化铵 、 锌 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 8.0h， 生成 6-(morpholinomethyl)benzo[d]thiazol-2-amine
  参考文献：
  名称：

  Identification of benzothiazoles as novel PCSK9 inhibitors

  摘要：

  DOI：

  10.1016/j.bmcl.2023.129542

文献信息

• Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold
  作者：Guanglong Bao、Baoquan Du、Yuxiu Ma、Meng Zhao、Ping Gong、Xin Zhai

  DOI：10.2174/1573406412666160107113343

  日期：2016.6.23

  Two series of novel benzothiazole derivatives conjugated with semicarbazone scaffold were designed and synthesized through a structure-based molecular hybridization strategy. All the target compounds were evaluated for their cytotoxicity in vitro against three cancer cell lines (HT-29, MKN-45 and H460) by standard MTT assay. The pharmacological results indicated that seven compounds (17h-n) exhibited

  通过基于结构的分子杂交策略，设计并合成了两类新颖的结合了半脲酮骨架的苯并噻唑衍生物。通过标准MTT测定法评估了所有目标化合物在体外对三种癌细胞系（HT-29，MKN-45和H460）的细胞毒性。药理结果表明，与参考药物索拉非尼和PAC-1相比，七种化合物（17h-n）表现出可比甚至更好的抗增殖活性。尤其是，化合物17i对测试的三种癌细胞系表现出显着的细胞毒性，IC50值分别为0.84、0.06和0.52 µM，分别比索拉非尼强4.3倍，36.6倍，4.2倍，并且比索拉非尼高1.2倍，13.7倍，6.9倍分别比PAC-1活跃。
• 2,3-DIHYDROBENZOFURAN-5YL COMPOUNDS AS DYRK KINASE INHIBITORS
  申请人：4SC DISCOVERY GMBH

  公开号：US20160137637A1

  公开（公告）日：2016-05-19

  The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R 1 , R 2 , R 3 , R 4 , R A , X 1 , and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.

  本发明涉及以下公式（I）的化合物，其生理学功能衍生物或盐，其中R1，R2，R3，R4，RA，X1和A组，以及变量n，m和p的详细信息在此进一步说明。在另一方面，本发明提供了制备它们的方法，它们的医学用途和包含所述化合物、生理学功能衍生物、溶剂化物或其盐的制药组合物。
• 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors
  申请人：4SC DISCOVERY GMBH

  公开号：US10005769B2

  公开（公告）日：2018-06-26

  The present invention relates to compounds of below Formula (I), physiologically functional derivatives or salts thereof, where the groups R1, R2, R3, R4, RA, X1, and A, as well as the variables n, m and p are detailed further herein. In another aspect, the present invention provides methods for their preparation, their medical use and pharmaceutical compositions comprising said compounds, physiologically functional derivatives, solvates or salts thereof.

  本发明涉及下式（I）化合物、其生理功能衍生物或盐类，其中基团 R1、R2、R3、R4、RA、X1 和 A 以及变量 n、m 和 p 在此进一步详述。 在另一方面，本发明提供了包含上述化合物、其生理功能衍生物、溶液或盐的制备方法、医疗用途和药物组合物。
• [EN] 2,3-DIHYDROBENZOFURAN-5-YL COMPOUNDS AS DYRK KINASE INHIBITORS<br/>[FR] COMPOSÉS 2,3-DIHYDROBENZOFURAN-5-YL UTILISÉS COMME INHIBITEURS DE KINASES DYRK
  申请人：4SC DISCOVERY GMBH

  公开号：WO2014202638A9

  公开（公告）日：2016-03-03